{"id":538,"date":"2018-11-05T09:00:00","date_gmt":"2018-11-05T09:00:00","guid":{"rendered":"https:\/\/isosolution-v2.staging.xiyx.ai\/news\/safety-pharmacokinetics-and-dosimetry-of-a-long-acting-radiolabeled-somatostatin-analog-177lu-dota-eb-tate-in-patients-with-advanced-metastatic-neuroendocrine-tumors\/"},"modified":"2018-11-05T09:00:00","modified_gmt":"2018-11-05T09:00:00","slug":"safety-pharmacokinetics-and-dosimetry-of-a-long-acting-radiolabeled-somatostatin-analog-177lu-dota-eb-tate-in-patients-with-advanced-metastatic-neuroendocrine-tumors","status":"publish","type":"iso_news","link":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/news\/safety-pharmacokinetics-and-dosimetry-of-a-long-acting-radiolabeled-somatostatin-analog-177lu-dota-eb-tate-in-patients-with-advanced-metastatic-neuroendocrine-tumors\/","title":{"rendered":"Innocuit\u00e9, pharmacocin\u00e9tique et dosim\u00e9trie d'une somatostatine radiomarqu\u00e9e \u00e0 longue dur\u00e9e d'action Analogue 177Lu-DOTA-EB-TATE chez les patients pr\u00e9sentant des tumeurs neuroendocrines m\u00e9tastatiques avanc\u00e9es"},"content":{"rendered":"<p>L'analogue de la somatostatine radiomarqu\u00e9 est devenu une m\u00e9thode de traitement \u00e9tablie pour les patients pr\u00e9sentant des tumeurs neuroendocrines non r\u00e9s\u00e9cables ou m\u00e9tastatiques bien \u00e0 mod\u00e9r\u00e9ment diff\u00e9renci\u00e9es. Les analogues de la somatostatine les plus fr\u00e9quemment utilis\u00e9s en pratique clinique sont l'octr\u00e9otide et l'octr\u00e9otate.  <a href=\"https:\/\/isosolutions.com\/safety-pharmacokinetics-and-dosimetry-of-a-long-acting-radiolabeled-somatostatin-analog-177lu-dota-eb-tate-in-patients-with-advanced-metastatic-neuroendocrine-tumors\/\"><span aria-label=\"Continuer la lecture Innocuit\u00e9, pharmacocin\u00e9tique et dosim\u00e9trie d&#039;une somatostatine radiomarqu\u00e9e \u00e0 longue dur\u00e9e d&#039;action Analogue 177Lu-DOTA-EB-TATE chez les patients pr\u00e9sentant des tumeurs neuroendocriniennes m\u00e9tastatiques avanc\u00e9es\">(plus...)<\/span><\/a><\/p>\n<\/p><\/div>\n<p>\u00c9tiquettes : <a href=\"https:\/\/isosolutions.com\/news-tag\/isosolutions\/\" rel=\"tag\">isoSolutions<\/a> <a href=\"https:\/\/isosolutions.com\/news-tag\/lu-177\/\" rel=\"tag\">Lu-177<\/a> <a href=\"https:\/\/isosolutions.com\/news-tag\/radiochemicals\/\" rel=\"tag\">Produits radiochimiques<\/a> <a href=\"https:\/\/isosolutions.com\/news-tag\/research\/\" rel=\"tag\">Recherche<\/a><\/p>\n<\/p><\/div>","protected":false},"excerpt":{"rendered":"<p>L'analogue de la somatostatine radiomarqu\u00e9 est devenu une m\u00e9thode de traitement \u00e9tablie pour les patients pr\u00e9sentant des tumeurs neuroendocrines non r\u00e9s\u00e9cables ou m\u00e9tastatiques bien \u00e0 mod\u00e9r\u00e9ment diff\u00e9renci\u00e9es. Les..<\/p>","protected":false},"featured_media":564,"template":"","iso_news_section":[43],"class_list":["post-538","iso_news","type-iso_news","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/iso_news\/538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/iso_news"}],"about":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/types\/iso_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/media\/564"}],"wp:attachment":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/media?parent=538"}],"wp:term":[{"taxonomy":"iso_news_section","embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/fr\/wp-json\/wp\/v2\/iso_news_section?post=538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}